A CDSCO medical device licence is not a finish line. Manufacturing sites move, designs get refined, labels get updated, agents and company structures change, and each event raises the same question. Does it need a Post-Approval Change Application, an endorsement, a fresh licence or just an internal record?
This article works through what a CDSCO Change Application actually involves, based on the Medical Device Rules, 2017 and current official CDSCO guidance.
What Is a CDSCO Post-Approval Change Application?
A CDSCO Post-Approval Change Application is the mechanism by which a licensee informs CDSCO when something about an already-licensed device or its manufacturing site details no longer matches what was originally approved. It is also for obtaining approval where require.
The underlying principle is simple. The licence on record has to reflect the device and the company as they actually exist.
Not every change needs the same regulatory response. CDSCO’s Sixth Schedule under MDR 2017 divides post-approval changes into major and minor categories, and the two are handled very differently. Some changes, such as a change in company constitution or a change of Indian Authorised Agent, fall outside the standard major or minor change framework entirely and instead trigger fresh licence requirements.
Internal quality-system change control, regulatory notification, licence endorsement and a fresh licence application are four distinct outcomes. A well-run CDSCO Change Control process starts by working out which one applies before anything gets filed.
What Types of Changes Require CDSCO Approval or Endorsement?
Six categories of change come up most often in practice, and each one carries a different regulatory expectation.
- Manufacturing site changes. A new facility, an additional site, relocation of an existing site or a shift in which functions are performed where, all fall within scope. Official CDSCO guidance confirms that a change in the location of an approved manufacturing site must be reported to the Licensing Authority through the post-approval change route, with further action depending on what CDSCO’s review finds.
- Design and specification changes. Anything that could affect safety, performance, intended use or the device’s approved specifications sits squarely in major-change territory under the Sixth Schedule.
- Labelling and packaging changes. CDSCO’s own FAQ guidance states plainly that label changes, other than adjustments to font size, font type, colour or general label design, are treated as major changes. That exemption is more limited than many manufacturers assume, and it means most substantive label content changes need formal review, not a quiet update.
- Change in company constitution. Mergers, changes in ownership and shifts in legal entities fall under Rule 3(j) of MDR 2017. This is one of the few post-approval events where a fresh licence is the confirmed regulatory outcome.
- Change of Indian Authorised Agent. This is worth stating precisely because it surprises so many manufacturers. Current official CDSCO guidance confirms that a change in the Indian Authorised Agent requires a fresh import licence. There is no endorsement or transfer mechanism for moving an existing import licence to a new agent.
- Addition of models or variants. These are typically handled through an endorsement application to the existing licence, supported by the requisite fee and documentation under the Fourth Schedule.
CDSCO Change Control: How Manufacturers Should Assess a Proposed Change
Before anything gets filed, it helps to work through a short set of questions.
- What exactly is changing?
- Does it affect the approved device’s safety or intended use?
- Does it touch the manufacturing location?
- Does it alter the legal entity behind the licence?
- Does it affect labelling?
- Does it require updates to technical documentation?
- Does the existing CDSCO licence still describe the product and the company accurately once the change is made?
CDSCO Post-Approval Change Application Process
The steps below apply broadly across change types, though the depth of documentation and the regulatory outcome will differ depending on how the change is classified.
Step 1. Identify and document the proposed change.
Define the current approved condition, the proposed condition, the reason for the change, the intended effective date and which products and regulatory documents are affected.
Step 2. Assess the regulatory impact.
Work out whether the change needs only an internal record, a notification, an endorsement, a licence amendment or a fresh licence application. This assessment should rest on the Sixth Schedule and current CDSCO guidance, not on assumption.
Step 3. Review the existing CDSCO licence.
The licence already on file, whether issued in Form MD-9 for Class C or D manufacturing, Form MD-13 for a manufacturing test licence or Form MD-14/MD-15 for import, is the reference point against which the proposed change is measured.
Step 4. Prepare supporting documentation.
Because CDSCO Change Application Requirements vary by change type, the documentation package should be built around what the specific change actually touches.
Step 5. Submit through the applicable CDSCO online system.
Post-approval changes are filed through CDSCO’s online portal infrastructure, commonly referred to as the Sugam or Medical Devices Online portal. Not every change type follows an identical workflow within that system.
Step 6. Respond to CDSCO queries.
Reviewers routinely raise clarification requests covering technical detail, missing annexures, formatting issues or inconsistencies between the application and supporting documents.
Step 7. Receive the regulatory outcome.
The result depends on the nature of the change. A major change requires CDSCO approval before implementation. A minor change can generally proceed once CDSCO has been notified within the required window, without needing to wait for a formal approval.
CDSCO Change Application Requirements and Documents
Depending on the change, documentation may include:
- The existing CDSCO licence
- The relevant application form
- A justification for the change
- A before-and-after comparison
- Updated technical documentation
- Updated labelling or packaging information
- Updated manufacturing site details
- Quality documentation and risk assessment records
- Verification or validation evidence
- Company or legal documents
- Authorised Agent documentation
- Supporting certificates
Not every item applies to every submission. What CDSCO actually asks for depends on the scope and category of the specific change and the checklist published on the Medical Devices Online portal for post-approval changes is the authoritative reference for a given filing.
CDSCO Medical Device License Amendment and Endorsement
Licence amendment, endorsement, change application, and fresh licence application are related but distinct outcomes, and CDSCO does not use them interchangeably.
An endorsement adds or updates specific details on an existing licence, such as an additional model or variant, and remains valid only for as long as the underlying base licence remains valid. A CDSCO Medical Device License Amendment more broadly covers updates to what is recorded against an existing licence.
A fresh licence application, by contrast, starts a new regulatory record entirely, and applies to defined situations such as change of company constitution, change of Indian Authorised Agent or relocation of the actual manufacturing site. Getting these three concepts confused, treating an endorsement-eligible change as though it needs a fresh licence, or the reverse, is a frequent and costly error.
The licence form already on file is usually the starting reference point for working out what a change actually affects.
| CDSCO Form | Applies To | Typical Relevance to a Change Application |
| MD-9 | Manufacturing licence, Class C and Class D devices |
Reference point for manufacturing site, design or specification changes
|
| MD-13 | Manufacturing test licence (test, evaluation, demonstration, training) |
Relevant where a change affects test batches or trial-stage manufacturing
|
| MD-14 | Import licence application (Class C and Class D) |
Application form reviewed alongside a proposed import-side change
|
| MD-15 | Import licence, Class C and Class D devices |
Reference point for import-side site, agent, product or company constitution changes
|
CDSCO Manufacturing Site Change
A CDSCO Manufacturing Site Change covers adding a new site, relocating an existing one, redistributing manufacturing functions across sites or bringing a contract manufacturer into scope. Each of these needs to be reported to the Licensing Authority, with the specific regulatory action depending on CDSCO’s assessment of the change.
For imported devices specifically, a change in the location of the actual overseas manufacturing site requires a fresh import licence rather than a notification. This is a narrower and stricter rule than the one that applies to domestic manufacturing site changes, and manufacturers relying on the general post-approval change route by default can get this wrong.
Supporting documentation typically needs to reflect the updated Plant Master File and, where applicable, updated Device Master File references. Manufacturers should also check whether any linked endorsements need to be updated in parallel, since a site change that isn’t reflected consistently across the full documentation stack is a common source of review queries.
CDSCO Medical Device Labelling Change
Not every label revision requires a CDSCO Medical Device Labelling Change filing. Official guidance draws the line clearly. Changes to font size, font type, colour or general label design fall outside the major-change category.
Changes to substantive content, including product claims, intended use statements, manufacturer or manufacturing information, or device identification details, are treated as major changes requiring approval. Instructions for use and product information should be reviewed against this same standard before a label update goes to print.
Indian Authorised Agent Change CDSCO
The Indian Authorised Agent is the entity through which an overseas manufacturer’s import licence operates in India, appointed by power of attorney. Changing the agent requires a fresh import licence, as per CDSCO guidance.
There is no mechanism to endorse or transfer the existing import licence to a new agent, and the earlier licence does not carry forward automatically. This has practical consequences for timeline and cost that catch manufacturers who assume an endorsement will suffice.
Manufacturers, and any overseas manufacturer, must also inform the Licensing Authority in writing within forty-five days of a change affecting the Authorised Agent or the overseas manufacturer’s constitution.
CDSCO Sugam Portal Change Application
Post-approval changes for medical devices are filed online through CDSCO’s Medical Devices Online portal. Although this portal is often referred to as the “Sugam” system in industry, it is technically separate from CDSCO’s Sugam portal for drugs and clinical trials. The portal handles application submission, supporting document uploads, application tracking and query correspondence with the reviewing office.
Portal forms and expected annexures are periodically updated as CDSCO issues fresh FAQ addenda and guidance. Because of this, it’s worth checking the current checklist on the portal at the time of filing rather than relying on a checklist used for an earlier submission.
CDSCO Change Application Timeline
CDSCO does not publish a single guaranteed timeline covering every type of post-approval change. What official guidance does establish is a framework tied to change classification, and the same classification also determines whether a fee applies.
| Change Category | Prior Approval Needed | Official Timeline | Fee |
| Major change, manufacturing | Yes | 45 days, subject to satisfactory data |
Fee under the Second Schedule of MDR 2017
|
| Major change, import | Yes | 60 days, subject to satisfactory data |
Fee under the Second Schedule of MDR 2017
|
| Minor change | No | Notify CDSCO within 30 days of the change taking effect | No fee |
Actual processing time in any individual case depends on submission completeness, documentation quality, and whether CDSCO raises clarification queries.
CDSCO Change Application Fees
CDSCO’s own FAQ guidance draws a clear line on fees, as set out in the table above. Major changes may attract a fee under the Second Schedule of MDR 2017. Minor changes do not require a fee at all, since they proceed on notification rather than prior approval.
Beyond that general rule, CDSCO does not appear to publish a separate, itemised fee specific to each individual type of post-approval change.
Government fees, licence retention fees, endorsement-related costs, and any testing or documentation costs incurred to support a submission are separate line items and shouldn’t be treated as a single bundled figure.
Common Problems with CDSCO Post-Approval Change Applications
A few problems show up repeatedly in practice.
- Manufacturers misclassify a change, treating something that needs formal CDSCO review as an internal quality matter only, or the reverse.
- Supporting documents arrive incomplete or inconsistent with the technical documentation already on file.
- Labelling submitted with the application doesn’t match what was actually approved.
- Annexures go missing or don’t follow the current portal format.
- Authorised Agent or company constitution changes get filed as endorsements when a fresh licence was actually required.
- Query responses, when CDSCO does raise questions, come back slowly or don’t fully address what was asked, stretching what should have been a routine filing into a multi-month exchange.
How to Prepare a Strong CDSCO Change Application
The strongest applications treat the change as one coherent story rather than a single form. That means checking that the CDSCO application, the existing licence, the Device Master File, technical documentation, risk management records, verification and validation evidence, labelling, packaging, manufacturing information and Authorised Agent details all describe the same change consistently.
A design change that shows up in the technical file but not in the risk management documentation, or a site change reflected in the application but not in the updated Plant Master File, is exactly the kind of gap that invites a CDSCO query.
Role of Regulatory Consultants in CDSCO Post-Approval Changes
Regulatory support tends to matter most in three areas.
Change triage. An honest assessment of whether a proposed change genuinely needs an endorsement, a fresh licence or just internal documentation, based on current CDSCO practice rather than a generic checklist.
Documentation coordination. Making sure every affected document tells the same story.
Portal and query management. Tracking a submission through the online system and responding to CDSCO’s clarification questions promptly and in regulatory language the reviewer can act on.
These are practical observations about where support adds value.
Conclusion
Managing CDSCO post-approval changes is an ongoing part of holding a medical device licence in India, not a one-time filing exercise.
The decision that matters most happens before anything reaches the Sugam portal. It is working out on what regulatory action a proposed change actually needs. Manufacturers that make that assessment early and keep their full documentation stack aligned once a change is confirmed, generally avoid the delays that turn a routine update into a prolonged review.
If support is needed with CDSCO post-approval change applications, licence amendments, endorsements, documentation or regulatory change assessment, reach out to the experts at info@artixio.com for guidance tailored to specific medical device and India market requirements.
FAQs
Q1. What is a CDSCO Post-Approval Change Application?
It is the regulatory mechanism used to inform CDSCO and obtain approval where required, when a device or company detail changes after a CDSCO licence has already been granted.
Q2. Which medical device changes require CDSCO approval?
Major changes under the Sixth Schedule of MDR 2017, such as those affecting device specifications, indication for use, performance or stability, require prior CDSCO approval before implementation.
Q3. How do I change the Indian Authorised Agent with CDSCO?
Current CDSCO guidance requires a fresh import licence application. There is no endorsement or transfer route for moving an existing import licence to a new Authorised Agent.
Q4. Does a labelling change require a CDSCO change application?
It depends on what changes. Font size, font type, colour and label design changes fall outside the major-change category. Substantive content changes are treated as major changes requiring approval.
Q5. How long does a CDSCO change application take?
Official guidance sets 45 days for major manufacturing changes and 60 days for major import changes, provided the data submitted is satisfactory. Minor changes need only be notified within 30 days after taking effect, without a prior-approval wait.
Q6. Is a fresh CDSCO licence required for every post-approval change?
No. Many changes are handled through endorsement or notification. A fresh licence is required for defined situations, including change of company constitution and change of Indian Authorised Agent.
